Reservations to get injected with SKYCovione, Korea's first domestically developed vaccine against COVID-19 produced by the pharmaceutical company SK Bioscience, began on Sept. 1. (Yonhap News)
By Park Hye Ri
Reservations to get SKYCovione, Korea's first domestically developed vaccine against COVID-19, began on Sept. 1.
The Korea Disease Control and Prevention Agency said reservations for the vaccine, which was developed by SK Bioscience, began at midnight that day on the agency's website for making reservations for COVID-19 vaccines (ncvr.kdca.go.kr).
Jointly developed by SK and the University of Washington's School of Medicine, the vaccine contains synthetic antigens (genetic recombination) and gained approval in June from the National Institute of Food and Drug Safety Evaluation and approval for shipment on Aug. 26.
SKYCovione is used for the first two vaccine shots for unvaccinated people aged 18 or older.
Vaccination through reservation will start from Sept. 13 and walk-in injections will begin from Sept. 5 at public health centers and designated medical institutions.
hrhr@korea.kr